search
Back to results

Lowering Serum Uric Acid to Prevent Acute Kidney Injury (RasbAKI)

Primary Purpose

Hyperuricemia

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Rasburicase
Placebo
Sponsored by
University of Florida
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hyperuricemia focused on measuring cardiac surgery, hyperuricemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 years or older, and
  2. Undergoing elective cardiothoracic surgery(s), alone or in combination with other procedures/surgery(s): thoracic aortic aneurysm, cardiac valves, coronary artery bypass grafting, abdominal thoracic aneurysm, other CV surgery, and
  3. Preoperative serum uric acid > 6.5 mg/dL, and
  4. Preoperative estimated glomerular filtration rate of >30ml/min/1.73m2 or higher, but less than 60ml/min/1.73m2

Exclusion Criteria:

  1. Prior history of allergy/adverse reaction to Rasburicase
  2. History of any organ transplant
  3. Preoperative intra-aortic balloon pump (IABP)
  4. Known glucose 6-phosphate dehydrogenase (G6PD) deficiency
  5. Current use of natriuretic peptides

Sites / Locations

  • University of Florida

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Rasburicase

Placebo

Arm Description

patients receiving rasburicase to lower serum uric acid

patients will receive a placebo

Outcomes

Primary Outcome Measures

Number of Patients With Acute Kidney Injury (AKI).
Acute kidney injury will be defined as an increase in serum creatinine of 0.3mg/dL from baseline or a 50% increase in serum creatinine from baseline values within 48 hours after surgery.

Secondary Outcome Measures

Full Information

First Posted
September 19, 2008
Last Updated
August 1, 2012
Sponsor
University of Florida
search

1. Study Identification

Unique Protocol Identification Number
NCT00756964
Brief Title
Lowering Serum Uric Acid to Prevent Acute Kidney Injury
Acronym
RasbAKI
Official Title
Effect of Rasburicase on Acute Kidney Injury, Kidney Function, the Incidence of Renal Replacement Therapy and All-cause Mortality Following Cardiac Surgery.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
October 2008 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Florida

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Acute kidney injury is associated with a rise in serum uric acid during cardiovascular surgery and can cause poor blood flow to the kidneys making them vulnerable to kidney injury. We hypothesize that hyperuricemia, particularly if chronic and marked, is a risk factor for acute kidney injury. The preoperative lowering of serum uric acid will reduce the incidence of acute kidney injury following cardiovascular surgery.
Detailed Description
The study will be a prospective, double-blind, placebo-controlled, randomized, clinical trial, initiated and implemented conjointly by the Nephrology and Cardiovascular Surgery Departments at Shands Hospital at the University of Florida in Gainesville, FL. We propose to study whether lowering uric acid provides significant renal and cardiovascular protection in subjects undergoing cardiovascular surgery. Up to 30 patients presenting for elective or urgent cardiovascular surgery with uric acid level > 6.5 mg/dl and estimated glomerular filtration of 30 - 60 ml/min will be included in the study. Patients recruitment will continue until up to 30 patients have completed the study, taking into account expected patient loss due to withdrawal of consent, incomplete study and other reasons. Patients will be randomized to a control group or rasburicase group. Rasburicase or identical placebo will be administered to each group after randomization. A selected number of patients may undergo additional testing for mechanistic (non-clinical) secondary endpoints.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperuricemia
Keywords
cardiac surgery, hyperuricemia

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Rasburicase
Arm Type
Active Comparator
Arm Description
patients receiving rasburicase to lower serum uric acid
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
patients will receive a placebo
Intervention Type
Drug
Intervention Name(s)
Rasburicase
Other Intervention Name(s)
urate oxidase enzyme
Intervention Description
Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
inactive ingredient
Intervention Description
Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
Primary Outcome Measure Information:
Title
Number of Patients With Acute Kidney Injury (AKI).
Description
Acute kidney injury will be defined as an increase in serum creatinine of 0.3mg/dL from baseline or a 50% increase in serum creatinine from baseline values within 48 hours after surgery.
Time Frame
Within 48 hours postoperatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or older, and Undergoing elective cardiothoracic surgery(s), alone or in combination with other procedures/surgery(s): thoracic aortic aneurysm, cardiac valves, coronary artery bypass grafting, abdominal thoracic aneurysm, other CV surgery, and Preoperative serum uric acid > 6.5 mg/dL, and Preoperative estimated glomerular filtration rate of >30ml/min/1.73m2 or higher, but less than 60ml/min/1.73m2 Exclusion Criteria: Prior history of allergy/adverse reaction to Rasburicase History of any organ transplant Preoperative intra-aortic balloon pump (IABP) Known glucose 6-phosphate dehydrogenase (G6PD) deficiency Current use of natriuretic peptides
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
A. Ahsan Ejaz, MD
Organizational Affiliation
University of Florida
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
17699382
Citation
Ejaz AA, Mu W, Kang DH, Roncal C, Sautin YY, Henderson G, Tabah-Fisch I, Keller B, Beaver TM, Nakagawa T, Johnson RJ. Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol. 2007 Jan;2(1):16-21. doi: 10.2215/CJN.00350106. Epub 2006 Dec 6.
Results Reference
background

Learn more about this trial

Lowering Serum Uric Acid to Prevent Acute Kidney Injury

We'll reach out to this number within 24 hrs